Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.
Aim(s): The aim of this study was to determine the rate of long responders to everolimus and their tolerability and efficacy.
Materials and methods: Retrospective analysis of advanced, progressive NENs treated with Everolimus . Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th – 75th IQR).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rinzivillo M
To read the full abstract, please log into your ENETS Member account.